ReviewFrontiers in drug safety and regulation2025
Pharmacovigilance and bioethics: the importance of a neglected relationship.
Review in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines the critical, yet often neglected, link between bioethics and pharmacovigilance-disciplines that collectively aim to ground drug therapies in robust evidence and respect for patient rights. Despite their shared mission, scholarly dialogue between these fields remains sparse. This gap is bridged by tracing their historical foundations and addressing key ethical challenges in pharmacovigilance through the lens of four core bioethical principles: autonomy, beneficence, non-maleficence, and justice. For each principle, pivotal questions and illustrative examples are outlined, offering guidance on embedding ethical reasoning into pharmacovigilance practice. It is argued that while regulations, standard operating procedures, and digital tools are indispensable, they cannot alone resolve the ethical dilemmas posed by rapid scientific innovation, resource constraints, and global inequities, and they may reduce safety professionals to mere task executors. Consequently, it is imperative that alongside technical and regulatory progress, pharmacovigilance fosters the study and application of ethical principles in every aspect of its operation. This transformation will recast it from a purely technical function into an equitable guardian of public health, ensuring sound decision-making, promoting public trust, and delivering maximal benefit while upholding human dignity worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.